PBAC's latest decision on Tadalafil: Recommended (2024). Considered for Treatment of pulmonary arterial hypertension (PAH), specifically a new 60-tablet pack size to align treatment supply duration with combination endothelin receptor antagonist therapies.
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
2
first 2011
Submissions
2
2011 → 2024
Eligible population
Patients with pulmonary arterial hypertension treated with tadalafil in combination with endothelin receptor antagonists.
Therapy area
Cardiovascular
Line of therapy
Any
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
Tadalis 56-tablet pack
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated as the new pack size is therapeutically equivalent to the existing 56-tablet pack on a per-tablet basis.
Submission history
Nov 2011: Recommended with restriction · Authority Required